Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Type of study
Language
Publication year range
1.
Clin Case Rep ; 9(7): e04503, 2021 Jul.
Article in English | MEDLINE | ID: mdl-34257990

ABSTRACT

This case illustrates the need to consider SARS-CoV-2 infection as a catalyst for Coombs-negative hemolytic anemia as well as the potential for IVIG to serve as an effective treatment for the condition.

2.
Blood ; 104(9): 2746-51, 2004 Nov 01.
Article in English | MEDLINE | ID: mdl-15265791

ABSTRACT

Tumor/host-generated thrombin (endogenous thrombin) was investigated with tumor growth and metastasis experiments in mice by the use of hirudin, a highly potent specific inhibitor of thrombin. Pretreatment with hirudin inhibited tumor implantation in nude or syngeneic mice, following subcutaneous injection of 2 human and 2 murine tumors. Hirudin induced a considerable lag period in the appearance of tumor growth, compared with phosphate-buffered saline (PBS) treatment, but had no effect on established tumor nodule growth in vivo or on tumor growth in vitro. Hirudin treatment induced central necrosis of the tumor nodule compared with no effect with PBS treatment. Greater protection was noted with longer duration of treatment. Tumor seeding into blood was examined with green fluorescent protein (GFP)-labeled tumor cells. Hirudin inhibited seeding into the blood as well as systemic organs which varied from complete protection to 15- to 32-fold in the blood and 17- to 395-fold in the lung. Hirudin inhibited spontaneous metastases from subcutaneously implanted tumor by reducing the number of tumor nodules in the lungs. Mouse survival in animals injected subcutaneously with highly aggressive 4T1 cells revealed 5 of 5 deaths of PBS-treated animals on day 40 compared with no deaths with hirudin treatment, with prolongation of survival with hirudin treatment of 16 days to more than 31 days. Thus, endogenous thrombin contributes to tumor implantation, seeding, and spontaneous metastasis. A potent antithrombin agent should be of clinical benefit to patients with cancer.


Subject(s)
Neoplasm Metastasis , Neoplasm Transplantation/pathology , Thrombin/physiology , Animals , Cell Line, Tumor , Hirudins/pharmacology , Humans , Lung Neoplasms/etiology , Lung Neoplasms/secondary , Mice , Mice, Nude , Necrosis , Neoplastic Cells, Circulating/drug effects , Survival Rate , Transplantation, Heterologous , Transplantation, Isogeneic
3.
Blood ; 99(5): 1646-50, 2002 Mar 01.
Article in English | MEDLINE | ID: mdl-11861279

ABSTRACT

Angiogenesis is required for tumor growth and metastasis. It has recently been suggested that thrombin is a potent promoter of angiogenesis. We therefore examined the possibility that thrombin could be inducing the expression of angiopoietin-2 (Ang-2), necessary for remodeling. Human umbilical vein endothelial cells were incubated with or without thrombin (1 U/mL) for 1 to 24 hours and then examined for messenger RNA (mRNA) by Northern analysis. Enhanced mRNA expression (about 4-fold over baseline) was noted at 4 hours. Enhanced expression of Ang-2 mRNA was secondary to enhanced transcription (about 4-fold), with no effect on stabilization. Enhanced Ang-2 mRNA transcription was inhibited by H7 and PD98059, indicating the requirement of serine/threonine kinases as well as the mitogen-activated protein kinase pathway. Up-regulation of mRNA was associated with enhanced Ang-2 protein synthesis and secretion as assayed by immunoblot. Thrombin-induced secreted Ang-2 inhibited the binding of recombinant (35)S-Ang-1 to its Tie-2-Fc receptor, demonstrating functionality. Hirudin reversed this effect, demonstrating thrombin specificity. Thus, thrombin-induced tumorigenesis and metastasis is associated with enhanced Ang-2 protein synthesis and secretion via enhanced transcription of Ang-2. This could help explain how thrombin promotes angiogenesis.


Subject(s)
Endothelium, Vascular/metabolism , Protein Biosynthesis , Thrombin/pharmacology , Angiopoietin-2 , Coagulants/pharmacology , Endothelium, Vascular/cytology , Enzyme Inhibitors/metabolism , Humans , Kinetics , Neovascularization, Pathologic/etiology , Phosphotransferases/antagonists & inhibitors , Phosphotransferases/physiology , Proteins/genetics , Proteins/metabolism , RNA, Messenger/biosynthesis , RNA, Messenger/drug effects , Transcription, Genetic/drug effects , Umbilical Veins/cytology , Up-Regulation/drug effects
SELECTION OF CITATIONS
SEARCH DETAIL
...